Neurotherapy as a Complementary Approach for Beta-Thalassemia Intermedia

Area of Science:

• Integrative Medicine
• Hematology
• Complementary Therapies

Background:

• Beta-thalassemia intermedia (β-TI) is a genetic blood disorder causing chronic anemia due to ineffective red blood cell production.
• Current treatments like transfusions and medications have limitations, including risks of iron overload and inconsistent effectiveness.
• Alternative therapies are sought to improve patient outcomes without invasive procedures.

Observation:

• A 44-year-old female with β-TI received 48 neurotherapy sessions over three months.
• The therapy targeted pressure points to stimulate organs vital for hemoglobin synthesis (pancreas, kidneys, thyroid, liver).
• Interventions aimed to boost erythropoietin, enhance iron metabolism, and support globin chain production.

Findings:

• Hemoglobin increased from 5.9 to 9.7 g/dL; hematocrit, MCV, MCH, and MCHC improved.
• Ferritin levels decreased, while platelets, TSH, and ESR significantly reduced; Vitamin B12 normalized.
• The patient reported enhanced energy, reduced fatigue, and better physical tolerance with no adverse effects.

Implications:

• Neurotherapy may be a safe and effective adjunctive treatment for beta-thalassemia intermedia.
• This approach shows potential for improving hematological parameters and alleviating debilitating fatigue in β-TI patients.
• Further research into neurotherapy could expand treatment options for chronic anemia disorders.